BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

Listen to more stories on the Noa app. In May, I asked Google’s chatbot, Gemini, to write a birthday letter to my best friend. Within seconds, it spat out the most impressive piece of AI writing ...

The comments section is here to provide a platform for civil dialogue on the issues we face together as a local community. Xpress is committed to offering this platform for all voices, but when ...

EPA administrator Lee Zeldin had a sharp response to the employee-signed letter.

The four-page dissent letter, posted on the website for anti-Trump activist group Standup for Science, lays out several concerns EPA employees have with Administrator Lee Zeldin.

The Environmental Protection Agency (EPA) is placing staffers who signed a letter of dissent against the Trump administration’s actions and policies on leave. The EPA says it has placed 1… ...

Sen. Mark Warner (D-Va.) said in a Sunday interview that University of Virginia President James Ryan, who submitted his resignation on Friday, was given an “explicit” deadline to step aside ...